Log In
BCIQ
Print this Print this
 

APVO425

  Manage Alerts
Collapse Summary General Information
Company Aptevo Therapeutics Inc.
DescriptionHumanized, bispecific ADAPTIR molecule targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and CD3
Molecular Target Receptor tyrosine kinase-like orphan receptor 1 (ROR1) ; CD3
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat triple-negative breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today